Oncolytic Viral Immunotherapies for Cancer
Total Trials
12
As Lead Sponsor
11
As Collaborator
1
Total Enrollment
1,278
NCT00751270
Phase 1b Study of AdV-tk + Valacyclovir Combined With Radiation Therapy for Malignant Gliomas
Phase: Phase 1
Role: Lead Sponsor
Start: Nov 30, 2005
Completion: Jan 31, 2011
NCT00589875
Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma
Phase: Phase 2
Start: Mar 31, 2007
Completion: Aug 31, 2016
NCT00638612
AdV-tk Therapy With Surgery and Chemoradiation for Pancreas Cancer (PaTK01)
Start: Aug 31, 2008
Completion: Jun 30, 2015
NCT00634231
A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors
Start: Oct 31, 2010
Completion: Jun 30, 2021
NCT01436968
Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer
Phase: Phase 3
Start: Sep 30, 2011
Completion: Dec 31, 2030
NCT01997190
Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion
Start: Oct 31, 2013
Completion: Feb 28, 2018
NCT02446093
Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinoma
Start: Oct 31, 2015
Completion: Jul 31, 2026
NCT02768363
Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)
Start: May 31, 2016
Completion: Dec 31, 2026
NCT03131037
Intratumoral Gene Mediated Cytotoxic Immunotherapy in Patients With Resectable Non-Small Cell Lung Cancer
Start: May 4, 2017
Completion: Sep 20, 2023
NCT03152318
A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2
Role: Collaborator
Start: Jul 18, 2017
Completion: Jan 31, 2027
NCT03576612
GMCI, Nivolumab, and Radiation Therapy in Treating Patients With Newly Diagnosed High-Grade Gliomas
Start: Feb 27, 2018
Completion: Jun 30, 2023
NCT04495153
CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC
Start: Oct 13, 2020
Loading map...